Post-transfusional iron overload, iron loading anemia;Surcharge en fer d'origine hématologique

Revue de Medecine Interne

Volumn 33, Issue SUPPL. 1, 2012, Pages

  Rose, C ^a  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

Deferasirox; Deferiprone; Iron loading anemia; Post transfusional iron overload; Transfusion

Indexed keywords

ANEMIA; ARTICLE; BLOOD TRANSFUSION; IRON OVERLOAD; IRON THERAPY;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; BLOOD TRANSFUSION; CHELATION THERAPY; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 84861225939     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.03.001     Document Type: Article

References (18)

1. Fleming R.E., Ponka P. Iron overload in human disease. N Engl J Med 2012, 366(4):348-359.
2. Piga A, Roggero S, Longo F, Ernst O, Rose C. The handbook: disorders of erythropoiesis, erythrocytes and iron metabolism. Chapter 24: evaluation and treatment of secondary iron overload 2009:584-604.
3. Tamary H., Shalev H., Perez-Avraham G., Zoldan M., Levi I., Swinkels D.W., et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008, 112(13):5241-5244.
4. Thuret I., Pondarre C., Loundou A., Steschenko D., Girot R., Bachir D., et al. Complications and treatment of patients with beta-thalassemia in France: results of the National Registry. Haematologica 2010, 95(5):724-729.
5. Renella R., Wood W.G. The congenital dyserythropoietic anemias. Hematol Oncol Clin North Am 2009, 23(2):283-306.
6. Harmatz P., Butensky E., Quirolo K., Williams R., Ferrell L., Moyer T., et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000, 96(1):76-79.
7. Fenaux P., Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009, 23(Suppl 1):S15-S19.
8. Rose C., Ernst O., Hecquet B., Maboudou P., Renom P., Noel M.P., et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica 2007, 92(6):850-853.
9. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363(9406):357-362.
10. Pennell D.J. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005, 1054:373-378.
11. Rose C., Vandevenne P., Bourgeois E., Cambier N., Ernst O. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol 2006, 77(2):145-149.
12. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109(10):4586-4588.
13. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364(2):146-156.
14. Piga A., Galanello R., Forni G.L., Cappellini M.D., Origa R., Zappu A., et al. Randomized phase II trial of deferasirox (Exjade ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006, 91(7):873-880.
15. Cappellini M.D., Porter J., El-Beshlawy A., Li C.K., Seymour J.F., Elalfy M., et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010, 95(4):557-566.
16. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010, 34(7):864-870.
17. Gattermann N., Finelli C., Porta M.D., Fenaux P., Ganser A., Guerci-Bresler A., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34(9):1143-1150.
18. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107(9):3733-3737.